Ialuset is a medical device based on high molecular weight hyaluronic acid, designed to maintain a moist environment conducive to the healing of superficial wounds. Its popularity on social media as an anti-aging treatment has blurred the line between validated medical indication and self-prescribed cosmetic use, with direct consequences on coverage by Health Insurance.
Reimbursement for Ialuset after a dermatological procedure: the real conditions
The issue that generates the most disappointment concerns post-procedure scars. After laser treatment, surgical excision, or a medical peel, there is a strong temptation to request a prescription for Ialuset to accelerate skin repair. Coverage does not operate on this logic.
The reimbursement of Ialuset is based on its listing in the list of reimbursable products and services (LPP). This listing limits coverage to validated indications: ulcers, pressure sores, superficial burns. A scar resulting from an aesthetic procedure or a superficial laser treatment does not fall into these categories, even with a properly written prescription.
For acne scars without active wounds, the situation is the same. Cystic acne can leave deep atrophic marks, and Ialuset is sometimes recommended in the post-inflammatory phase. The reimbursement framework does not cover this situation. Obtaining a prescription does not guarantee coverage: it is compliance with the LPP indication that triggers reimbursement, not mere prescription.
In practice, to avoid a denial, the doctor must explicitly mention a recognized indication on the prescription. A vague wording like “post-treatment healing” is likely to be rejected during the compliance check. Detailed information on dermatologist reviews and reimbursement of Ialuset cream helps better anticipate these situations before going to the pharmacy.
Ialuset cream and Ialuset Plus: regulatory distinction and prescriber choice
The two versions of the product do not meet the same clinical needs. Ialuset cream contains only hyaluronic acid. Its function is physical: to create a moisturizing film that promotes cell migration on the surface of the wound.
Ialuset Plus combines hyaluronic acid with silver sulfadiazine, an antibacterial agent. This combination is intended for wounds at risk of infection (second-degree burns, infected ulcers). Its reimbursement follows more restrictive criteria, as the indication must justify the anti-infective component.
A dermatologist chooses between the two formulations based on several criteria:
- The presence or absence of signs of local infection (peripheral redness, purulent exudate, odor)
- The depth of the lesion and its healing stage (inflammatory, proliferative, or remodeling phase)
- History of allergy to sulfonamides, which formally contraindicates Ialuset Plus
Applying Ialuset Plus on healthy facial skin for cosmetic purposes exposes one to unnecessary contact with silver sulfadiazine, an active ingredient that has no reason to be used outside of an infectious context.
Topical hyaluronic acid on healthy skin: what dermatologists observe
The hyaluronic acid in Ialuset has a high molecular weight. This characteristic allows it to retain water on the surface and form a protective film over a wound. On intact skin, this same mechanism produces a temporary moisturizing effect, but does not penetrate the deeper layers of the dermis.
The confusion arises from the amalgamation with injectable hyaluronic acid used in aesthetic medicine. Injections place the product directly into the dermis, where it fills wrinkles by volumizing effect. The topical application of Ialuset does not reproduce this effect. Dermatologists who speak on this subject remind that the perceived anti-aging benefit corresponds to superficial hydration, reversible upon cessation of application.
The Haute Autorité de Santé (HAS), via the CNEDiMTS, evaluated the service provided by Ialuset on May 5, 2020. The verdict: service provided sufficient only for the treatment of wounds. No validation has been granted for cosmetic use on the face.
Preparing your reimbursement file: pitfalls to avoid at the pharmacy
A denial of reimbursement does not always manifest at the counter. The pharmacist dispenses the product on prescription, but the rejection can occur downstream, during the processing of the file by the health insurance fund.
To secure coverage, several elements must be included on the prescription:
- The precise indication corresponding to the LPP (type of wound, location, clinical context)
- The mention of the medical device by its exact commercial name, with the prescribed format
- The estimated duration of treatment, consistent with the type of lesion described
A prescription written for “facial healing care” or “post-laser hydration” does not correspond to any line of the LPP. The prescribing doctor must adapt the wording to the terms recognized by the framework. The patient should verify this point before leaving the office, as once the prescription is filled, correction becomes more complex.
The case of superficial burns remains the simplest to get reimbursed. The wound is visible, the indication directly corresponds to the LPP framework, and the duration of treatment is short. For chronic ulcers or pressure sores, regular medical follow-up constitutes additional proof in case of a check.
The gap between the popularity of Ialuset as a facial treatment and its strict regulatory framework will not diminish as long as its classification remains that of a wound healing medical device. Before any purchase, the pertinent question is not “does it work on my skin” but “does my indication correspond to what the LPP recognizes”.